- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Neuroendocrine Tumor Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Neuroendocrine Tumor Treatment market size is estimated to be worth US$ 1538.6 million in 2021 and is forecast to a readjusted size of USD 2260 million by 2028 with a CAGR of 5.6% during review period. Hospitals accounting for % of the Neuroendocrine Tumor Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Everolimus segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Neuroendocrine Tumor Treatment include Exelixis, Inc., Advanced Accelerator Applications, Dauntless Pharmaceuticals, Inc., Hutchinson Medipharma Limited, and Ispen, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neuroendocrine Tumor Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Everolimus
Sunitinib
Lu-Dotatate
Lanreotide
Octreotide
Market segment by Application, can be divided into
Hospitals
Clinic
Others
Market segment by players, this report covers
Exelixis, Inc.
Advanced Accelerator Applications
Dauntless Pharmaceuticals, Inc.
Hutchinson Medipharma Limited
Ispen
Novartis AG
Progenics Pharmaceuticals, Inc.
Tarveda Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Neuroendocrine Tumor Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Neuroendocrine Tumor Treatment, with revenue, gross margin and global market share of Neuroendocrine Tumor Treatment from 2019 to 2022.
Chapter 3, the Neuroendocrine Tumor Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Neuroendocrine Tumor Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Neuroendocrine Tumor Treatment research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of Neuroendocrine Tumor Treatment
1.2 Classification of Neuroendocrine Tumor Treatment by Type
1.2.1 Overview: Global Neuroendocrine Tumor Treatment Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Neuroendocrine Tumor Treatment Revenue Market Share by Type in 2021
1.2.3 Everolimus
1.2.4 Sunitinib
1.2.5 Lu-Dotatate
1.2.6 Lanreotide
1.2.7 Octreotide
1.3 Global Neuroendocrine Tumor Treatment Market by Application
1.3.1 Overview: Global Neuroendocrine Tumor Treatment Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Global Neuroendocrine Tumor Treatment Market Size & Forecast
1.5 Global Neuroendocrine Tumor Treatment Market Size and Forecast by Region
1.5.1 Global Neuroendocrine Tumor Treatment Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Neuroendocrine Tumor Treatment Market Size by Region, (2017-2022)
1.5.3 North America Neuroendocrine Tumor Treatment Market Size and Prospect (2017-2028)
1.5.4 Europe Neuroendocrine Tumor Treatment Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Neuroendocrine Tumor Treatment Market Size and Prospect (2017-2028)
1.5.6 South America Neuroendocrine Tumor Treatment Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Neuroendocrine Tumor Treatment Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuroendocrine Tumor Treatment Market Drivers
1.6.2 Neuroendocrine Tumor Treatment Market Restraints
1.6.3 Neuroendocrine Tumor Treatment Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 Exelixis, Inc.
2.1.1 Exelixis, Inc. Details
2.1.2 Exelixis, Inc. Major Business
2.1.3 Exelixis, Inc. Neuroendocrine Tumor Treatment Product and Solutions
2.1.4 Exelixis, Inc. Neuroendocrine Tumor Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Exelixis, Inc. Recent Developments and Future Plans
2.2 Advanced Accelerator Applications
2.2.1 Advanced Accelerator Applications Details
2.2.2 Advanced Accelerator Applications Major Business
2.2.3 Advanced Accelerator Applications Neuroendocrine Tumor Treatment Product and Solutions
2.2.4 Advanced Accelerator Applications Neuroendocrine Tumor Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Advanced Accelerator Applications Recent Developments and Future Plans
2.3 Dauntless Pharmaceuticals, Inc.
2.3.1 Dauntless Pharmaceuticals, Inc. Details
2.3.2 Dauntless Pharmaceuticals, Inc. Major Business
2.3.3 Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Product and Solutions
2.3.4 Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Dauntless Pharmaceuticals, Inc. Recent Developments and Future Plans
2.4 Hutchinson Medipharma Limited
2.4.1 Hutchinson Medipharma Limited Details
2.4.2 Hutchinson Medipharma Limited Major Business
2.4.3 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Product and Solutions
2.4.4 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Hutchinson Medipharma Limited Recent Developments and Future Plans
2.5 Ispen
2.5.1 Ispen Details
2.5.2 Ispen Major Business
2.5.3 Ispen Neuroendocrine Tumor Treatment Product and Solutions
2.5.4 Ispen Neuroendocrine Tumor Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Ispen Recent Developments and Future Plans
2.6 Novartis AG
2.6.1 Novartis AG Details
2.6.2 Novartis AG Major Business
2.6.3 Novartis AG Neuroendocrine Tumor Treatment Product and Solutions
2.6.4 Novartis AG Neuroendocrine Tumor Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Novartis AG Recent Developments and Future Plans
2.7 Progenics Pharmaceuticals, Inc.
2.7.1 Progenics Pharmaceuticals, Inc. Details
2.7.2 Progenics Pharmaceuticals, Inc. Major Business
2.7.3 Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Product and Solutions
2.7.4 Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Progenics Pharmaceuticals, Inc. Recent Developments and Future Plans
2.8 Tarveda Therapeutics
2.8.1 Tarveda Therapeutics Details
2.8.2 Tarveda Therapeutics Major Business
2.8.3 Tarveda Therapeutics Neuroendocrine Tumor Treatment Product and Solutions
2.8.4 Tarveda Therapeutics Neuroendocrine Tumor Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Tarveda Therapeutics Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global Neuroendocrine Tumor Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Neuroendocrine Tumor Treatment Players Market Share in 2021
3.2.2 Top 10 Neuroendocrine Tumor Treatment Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Neuroendocrine Tumor Treatment Players Head Office, Products and Services Provided
3.4 Neuroendocrine Tumor Treatment Mergers & Acquisitions
3.5 Neuroendocrine Tumor Treatment New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global Neuroendocrine Tumor Treatment Revenue and Market Share by Type (2017-2022)
4.2 Global Neuroendocrine Tumor Treatment Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global Neuroendocrine Tumor Treatment Revenue Market Share by Application (2017-2022)
5.2 Global Neuroendocrine Tumor Treatment Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America Neuroendocrine Tumor Treatment Revenue by Type (2017-2028)
6.2 North America Neuroendocrine Tumor Treatment Revenue by Application (2017-2028)
6.3 North America Neuroendocrine Tumor Treatment Market Size by Country
6.3.1 North America Neuroendocrine Tumor Treatment Revenue by Country (2017-2028)
6.3.2 United States Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
6.3.3 Canada Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
6.3.4 Mexico Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe Neuroendocrine Tumor Treatment Revenue by Type (2017-2028)
7.2 Europe Neuroendocrine Tumor Treatment Revenue by Application (2017-2028)
7.3 Europe Neuroendocrine Tumor Treatment Market Size by Country
7.3.1 Europe Neuroendocrine Tumor Treatment Revenue by Country (2017-2028)
7.3.2 Germany Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
7.3.3 France Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
7.3.5 Russia Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
7.3.6 Italy Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Neuroendocrine Tumor Treatment Revenue by Type (2017-2028)
8.2 Asia-Pacific Neuroendocrine Tumor Treatment Revenue by Application (2017-2028)
8.3 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Region
8.3.1 Asia-Pacific Neuroendocrine Tumor Treatment Revenue by Region (2017-2028)
8.3.2 China Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
8.3.3 Japan Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
8.3.4 South Korea Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
8.3.5 India Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
8.3.7 Australia Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America Neuroendocrine Tumor Treatment Revenue by Type (2017-2028)
9.2 South America Neuroendocrine Tumor Treatment Revenue by Application (2017-2028)
9.3 South America Neuroendocrine Tumor Treatment Market Size by Country
9.3.1 South America Neuroendocrine Tumor Treatment Revenue by Country (2017-2028)
9.3.2 Brazil Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
9.3.3 Argentina Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Neuroendocrine Tumor Treatment Revenue by Type (2017-2028)
10.2 Middle East & Africa Neuroendocrine Tumor Treatment Revenue by Application (2017-2028)
10.3 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Country
10.3.1 Middle East & Africa Neuroendocrine Tumor Treatment Revenue by Country (2017-2028)
10.3.2 Turkey Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
10.3.4 UAE Neuroendocrine Tumor Treatment Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Neuroendocrine Tumor Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Neuroendocrine Tumor Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Neuroendocrine Tumor Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Neuroendocrine Tumor Treatment Revenue (USD Million) by Region (2017-2022)
Table 5. Global Neuroendocrine Tumor Treatment Revenue Market Share by Region (2023-2028)
Table 6. Exelixis, Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Exelixis, Inc. Major Business
Table 8. Exelixis, Inc. Neuroendocrine Tumor Treatment Product and Solutions
Table 9. Exelixis, Inc. Neuroendocrine Tumor Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Advanced Accelerator Applications Corporate Information, Head Office, and Major Competitors
Table 11. Advanced Accelerator Applications Major Business
Table 12. Advanced Accelerator Applications Neuroendocrine Tumor Treatment Product and Solutions
Table 13. Advanced Accelerator Applications Neuroendocrine Tumor Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Dauntless Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 15. Dauntless Pharmaceuticals, Inc. Major Business
Table 16. Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Product and Solutions
Table 17. Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Hutchinson Medipharma Limited Corporate Information, Head Office, and Major Competitors
Table 19. Hutchinson Medipharma Limited Major Business
Table 20. Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Product and Solutions
Table 21. Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Ispen Corporate Information, Head Office, and Major Competitors
Table 23. Ispen Major Business
Table 24. Ispen Neuroendocrine Tumor Treatment Product and Solutions
Table 25. Ispen Neuroendocrine Tumor Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 27. Novartis AG Major Business
Table 28. Novartis AG Neuroendocrine Tumor Treatment Product and Solutions
Table 29. Novartis AG Neuroendocrine Tumor Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Progenics Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 31. Progenics Pharmaceuticals, Inc. Major Business
Table 32. Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Product and Solutions
Table 33. Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Tarveda Therapeutics Corporate Information, Head Office, and Major Competitors
Table 35. Tarveda Therapeutics Major Business
Table 36. Tarveda Therapeutics Neuroendocrine Tumor Treatment Product and Solutions
Table 37. Tarveda Therapeutics Neuroendocrine Tumor Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Global Neuroendocrine Tumor Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 39. Global Neuroendocrine Tumor Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 40. Breakdown of Neuroendocrine Tumor Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. Neuroendocrine Tumor Treatment Players Head Office, Products and Services Provided
Table 42. Neuroendocrine Tumor Treatment Mergers & Acquisitions in the Past Five Years
Table 43. Neuroendocrine Tumor Treatment New Entrants and Expansion Plans
Table 44. Global Neuroendocrine Tumor Treatment Revenue (USD Million) by Type (2017-2022)
Table 45. Global Neuroendocrine Tumor Treatment Revenue Share by Type (2017-2022)
Table 46. Global Neuroendocrine Tumor Treatment Revenue Forecast by Type (2023-2028)
Table 47. Global Neuroendocrine Tumor Treatment Revenue by Application (2017-2022)
Table 48. Global Neuroendocrine Tumor Treatment Revenue Forecast by Application (2023-2028)
Table 49. North America Neuroendocrine Tumor Treatment Revenue by Type (2017-2022) & (USD Million)
Table 50. North America Neuroendocrine Tumor Treatment Revenue by Type (2023-2028) & (USD Million)
Table 51. North America Neuroendocrine Tumor Treatment Revenue by Application (2017-2022) & (USD Million)
Table 52. North America Neuroendocrine Tumor Treatment Revenue by Application (2023-2028) & (USD Million)
Table 53. North America Neuroendocrine Tumor Treatment Revenue by Country (2017-2022) & (USD Million)
Table 54. North America Neuroendocrine Tumor Treatment Revenue by Country (2023-2028) & (USD Million)
Table 55. Europe Neuroendocrine Tumor Treatment Revenue by Type (2017-2022) & (USD Million)
Table 56. Europe Neuroendocrine Tumor Treatment Revenue by Type (2023-2028) & (USD Million)
Table 57. Europe Neuroendocrine Tumor Treatment Revenue by Application (2017-2022) & (USD Million)
Table 58. Europe Neuroendocrine Tumor Treatment Revenue by Application (2023-2028) & (USD Million)
Table 59. Europe Neuroendocrine Tumor Treatment Revenue by Country (2017-2022) & (USD Million)
Table 60. Europe Neuroendocrine Tumor Treatment Revenue by Country (2023-2028) & (USD Million)
Table 61. Asia-Pacific Neuroendocrine Tumor Treatment Revenue by Type (2017-2022) & (USD Million)
Table 62. Asia-Pacific Neuroendocrine Tumor Treatment Revenue by Type (2023-2028) & (USD Million)
Table 63. Asia-Pacific Neuroendocrine Tumor Treatment Revenue by Application (2017-2022) & (USD Million)
Table 64. Asia-Pacific Neuroendocrine Tumor Treatment Revenue by Application (2023-2028) & (USD Million)
Table 65. Asia-Pacific Neuroendocrine Tumor Treatment Revenue by Region (2017-2022) & (USD Million)
Table 66. Asia-Pacific Neuroendocrine Tumor Treatment Revenue by Region (2023-2028) & (USD Million)
Table 67. South America Neuroendocrine Tumor Treatment Revenue by Type (2017-2022) & (USD Million)
Table 68. South America Neuroendocrine Tumor Treatment Revenue by Type (2023-2028) & (USD Million)
Table 69. South America Neuroendocrine Tumor Treatment Revenue by Application (2017-2022) & (USD Million)
Table 70. South America Neuroendocrine Tumor Treatment Revenue by Application (2023-2028) & (USD Million)
Table 71. South America Neuroendocrine Tumor Treatment Revenue by Country (2017-2022) & (USD Million)
Table 72. South America Neuroendocrine Tumor Treatment Revenue by Country (2023-2028) & (USD Million)
Table 73. Middle East & Africa Neuroendocrine Tumor Treatment Revenue by Type (2017-2022) & (USD Million)
Table 74. Middle East & Africa Neuroendocrine Tumor Treatment Revenue by Type (2023-2028) & (USD Million)
Table 75. Middle East & Africa Neuroendocrine Tumor Treatment Revenue by Application (2017-2022) & (USD Million)
Table 76. Middle East & Africa Neuroendocrine Tumor Treatment Revenue by Application (2023-2028) & (USD Million)
Table 77. Middle East & Africa Neuroendocrine Tumor Treatment Revenue by Country (2017-2022) & (USD Million)
Table 78. Middle East & Africa Neuroendocrine Tumor Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Neuroendocrine Tumor Treatment Picture
Figure 2. Global Neuroendocrine Tumor Treatment Revenue Market Share by Type in 2021
Figure 3. Everolimus
Figure 4. Sunitinib
Figure 5. Lu-Dotatate
Figure 6. Lanreotide
Figure 7. Octreotide
Figure 8. Neuroendocrine Tumor Treatment Revenue Market Share by Application in 2021
Figure 9. Hospitals Picture
Figure 10. Clinic Picture
Figure 11. Others Picture
Figure 12. Global Neuroendocrine Tumor Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Neuroendocrine Tumor Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Neuroendocrine Tumor Treatment Revenue Market Share by Region (2017-2028)
Figure 15. Global Neuroendocrine Tumor Treatment Revenue Market Share by Region in 2021
Figure 16. North America Neuroendocrine Tumor Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Neuroendocrine Tumor Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Neuroendocrine Tumor Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Neuroendocrine Tumor Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Neuroendocrine Tumor Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Neuroendocrine Tumor Treatment Market Drivers
Figure 22. Neuroendocrine Tumor Treatment Market Restraints
Figure 23. Neuroendocrine Tumor Treatment Market Trends
Figure 24. Exelixis, Inc. Recent Developments and Future Plans
Figure 25. Advanced Accelerator Applications Recent Developments and Future Plans
Figure 26. Dauntless Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 27. Hutchinson Medipharma Limited Recent Developments and Future Plans
Figure 28. Ispen Recent Developments and Future Plans
Figure 29. Novartis AG Recent Developments and Future Plans
Figure 30. Progenics Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 31. Tarveda Therapeutics Recent Developments and Future Plans
Figure 32. Global Neuroendocrine Tumor Treatment Revenue Share by Players in 2021
Figure 33. Neuroendocrine Tumor Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 34. Global Top 3 Players Neuroendocrine Tumor Treatment Revenue Market Share in 2021
Figure 35. Global Top 10 Players Neuroendocrine Tumor Treatment Revenue Market Share in 2021
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 37. Global Neuroendocrine Tumor Treatment Revenue Share by Type in 2021
Figure 38. Global Neuroendocrine Tumor Treatment Market Share Forecast by Type (2023-2028)
Figure 39. Global Neuroendocrine Tumor Treatment Revenue Share by Application in 2021
Figure 40. Global Neuroendocrine Tumor Treatment Market Share Forecast by Application (2023-2028)
Figure 41. North America Neuroendocrine Tumor Treatment Sales Market Share by Type (2017-2028)
Figure 42. North America Neuroendocrine Tumor Treatment Sales Market Share by Application (2017-2028)
Figure 43. North America Neuroendocrine Tumor Treatment Revenue Market Share by Country (2017-2028)
Figure 44. United States Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe Neuroendocrine Tumor Treatment Sales Market Share by Type (2017-2028)
Figure 48. Europe Neuroendocrine Tumor Treatment Sales Market Share by Application (2017-2028)
Figure 49. Europe Neuroendocrine Tumor Treatment Revenue Market Share by Country (2017-2028)
Figure 50. Germany Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific Neuroendocrine Tumor Treatment Sales Market Share by Type (2017-2028)
Figure 56. Asia-Pacific Neuroendocrine Tumor Treatment Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific Neuroendocrine Tumor Treatment Revenue Market Share by Region (2017-2028)
Figure 58. China Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. South Korea Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Neuroendocrine Tumor Treatment Sales Market Share by Type (2017-2028)
Figure 65. South America Neuroendocrine Tumor Treatment Sales Market Share by Application (2017-2028)
Figure 66. South America Neuroendocrine Tumor Treatment Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East and Africa Neuroendocrine Tumor Treatment Sales Market Share by Type (2017-2028)
Figure 70. Middle East and Africa Neuroendocrine Tumor Treatment Sales Market Share by Application (2017-2028)
Figure 71. Middle East and Africa Neuroendocrine Tumor Treatment Revenue Market Share by Country (2017-2028)
Figure 72. Turkey Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. UAE Neuroendocrine Tumor Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
